Gilead to seek pause in U.S. government HIV PrEP suit until patent office rules on patent validity

Gilead plans to ask a federal court to pause a patent infringement lawsuit the federal government filed against the company’s Truvada and Descovy HIV pre-exposure prophylaxis (PrEP) drugs pending resolution of Gilead’s patent challenges by the U.S. Patent and Trademark Office.

The lawsuit, filed Wednesday by the U.S. government in the U.S. District Court for the District of

Read the full 587 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE